Boulder, CO, United States
Boulder, CO, United States
Time filter
Source Type

Dublin, April 17, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report to their offering. The global market for gastrointestinal disorder therapeutics and diagnostics reached $49.6 billion in 2015. This market is expected to grow from nearly $51.8 billion in 2016 to $63.8 billion in 2021 at a compound annual growth rate of 4.3% from 2016-2021. This report is designed to provide an in-depth look at the therapeutic and diagnostic options of various gastrointestinal disorders. The geographic scope of the report is global, with particular emphasis on the key markets such as the U.S. and the European Union Five (EU5). The estimated market data is also global in nature, with geographic segments such as the U.S., EU and Rest of the World (ROW). The report provides a brief overview of the gastrointestinal system, which provides an introduction to the disorders of the gastrointestinal system; cites risk factors, where applicable; presents current pharmaceutical treatments, market size and key market participants (both prescription and OTC); and presents potential treatments in R&D, potential market size and future market entrants. This report provides: - An overview of the global markets for gastrointestinal therapeutics and diagnostics. - Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021. - Analyses of therapeutics currently on the market as well as potential products and classes of products that are likely to have a significant impact. - Descriptions of the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future. - Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities. - Profiles of major players in the industry. The market for gastrointestinal pharmaceuticals is divided into two general segments: prescription gastrointestinal pharmaceuticals and OTC gastrointestinal pharmaceuticals. Similarly, the market for gastrointestinal diagnostics, testing and vaccines is divided into three general segments: - Diagnostics and testing market. - Medical devices (endoscopy) - Vaccines. The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system, including the following: - Gastrointestinal tract disorders. - Gastrointestinal tract walls disorders. - Gastrointestinal motility disorders. - Gastrointestinal cancers. Each sub-segment is covered in detail, describing the disorders and diseases, identifying currently available and potential products, and competitors. Key Topics Covered: 1: Introduction Complimentary - Study Goals And Objectives - Reasons For Doing The Study - Intended Audience - Scope Of Report - Methodology And Information Sources 2: Executive Summary - Gastrointestinal Therapeutics And Diagnostics 3: Overview - Gastric Cancer - Inflammatory Bowel Disease (IBD) - Constipation - Opioid-Induced Constipation - Gastroesophageal Reflux Disease 4: Etiology - Anatomy And Physiology Of The Gastrointestinal System - The Enteric Nervous System: An Overview - Factors Affecting The Functioning Of The GI System - Physiology Of The Gi System And The Role Of Each Part In The Gi Process 5: Prescription Therapy Market - Antidiarrheals - Antiemetics - Gastrointestinal Cancer Treatments - Gastroesophageal Reflux Disease Treatments - Proton Pump Inhibitors - Laxatives - Bowel Anti-Inflammatory - Other GI Drugs 6: OTC Therapy Market - Antacids - Locally Acting Antidiarrheals - H2 Inhibitors - Proton Pump Inhibitors - Laxatives - Total OTC Gastrointestinal Drug Market Size And Growth 7: Diagnostics And Devices Market - Enteric Disease Testing Methods - Global Market For Enteric Diagnostic Tests - Campylobacter - Norovirus - Rotavirus - Giardia Parasite - E. Coli - Cryptosporidium - Shigella - Typhoid - Amebiasis - Cholera - Other (H. Pylori, Yersinia) Diagnostic Tests - Medical Devices (Endoscopy) 8: Gastrointestinal Product Pipeline - Therapies For Treating Gastric Cancer - Gerd And Peptic Ulcers - Therapies For Treating IBS - Therapies For Treating Ulcerative Colitis And Crohn'S Disease 9: Patents 10: Company Profiles - Allergan Plc - Ardelyx Inc. - Astellas Pharma Inc. - Astrazeneca - Celgene Corp. - Clovis Oncology - Daewoong Pharmaceutical Co., Ltd. - ELI Lilly And Company - Glaxosmithkline - Horizon Pharma Plc - Immunogenx - Immunomedics - Merck & Co. - Merrimack Pharmaceuticals Inc. - New Link Genetics - Otsuka Holdings Co. Ltd. - Pfizer Inc. - Roche - Sanofi - Shire - Sucampo Pharmaceuticals Inc. - Synergy Pharmaceuticals Inc. - Synthetic Biologics - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceuticals - Valeant Pharmaceuticals For more information about this report visit

— Esophageal Cancer - Pipeline Market Review, H1 2017 is a new report added to The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 85 Tables and 11 Figures, 16 Company Profiles, Spread across 493 Pages Report Available at . Drug Profiles of Esophageal Cancer - 1-BB1, ADCT-502, ADXS-HER2, afatinib dimaleate, AL-3818, ALM-301, apatinib, APR-246, atezolizumab, ATL-101, BGBA-317, binimetinib, brontictuzumab, CBT-501, CDX-1401 many more. Main Companies are Adaptimmune Therapeutics Plc, ADC Therapeutics Sar, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC , Almac Discovery Ltd, Amgen Inc , Aprea AB , ArQule Inc , Array BioPharma Inc , Aslan Pharmaceuticals Pte Ltd , ATLAB Pharma SAS , Bayer AG , BeiGene Ltd , Beta Pharma Inc , Boehringer Ingelheim GmbH , Bristol-Myers Squibb Company , CBT Pharmaceuticals Inc , Celgene Corp , Celldex Therapeutics Inc, Cellectar Biosciences Inc, CellSeed Inc , Clovis Oncology Inc , Cyclacel Pharmaceuticals Inc , Eli Lilly and Company , F. Hoffmann-La Roche Ltd , Genmab A/S , GlaxoSmithKline Plc, Glycotope GmbH , Hutchison China MediTech Ltd , Ignyta Inc , Immunocore Ltd, ImmunoFrontier Inc , Immunomedics Inc , Intezyne Technologies Inc , Jiangsu Hengrui Medicine Co Ltd , Johnson & Johnson , Komipharm International Co Ltd , Leap Therapeutics Inc , MaxiVAX SA , Mebiopharm Co Ltd , MedImmune LLC , Merck & Co Inc , Novartis AG , Omeros Corp , Oncolys BioPharma Inc , OncoMed Pharmaceuticals Inc , Ono Pharmaceutical Co Ltd , Puma Biotechnology Inc, Rhizen Pharmaceuticals SA , Shionogi & Co Ltd , Spectrum Pharmaceuticals Inc , Stelic Institute & Co Inc , Supratek Pharma Inc 63, Symphogen A/S 63, Taiho Pharmaceutical Co Ltd 64, Taiwan Liposome Company Ltd 64, Takara Bio Inc 65, Transgene Biotek Ltd 65, VioQuest Pharmaceuticals Inc 66, XuanZhu Pharma Co Ltd. Place Order to This Report at Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery. The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 33, 28, 2, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 5, 2 and 1 molecules, respectively. Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology). • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology) About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the For more information, please visit

Clovis Oncology | Date: 2017-06-28

A tablet including high dosage of 8-fluoro-2-(4- [(methylamino)methyl]phenyl)-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed. The invention is directed to high dosage strength tablets of rucaparib. In some embodiments, the tablet includes 45-90% w/w njcaparib camsylate. In some embodiments, the dry granulated tablet includes 45-90% w/w rucaparib camsylate. One such embodiment is a tablet containing at least 200 mg rucaparib. Another embodiment is a tablet containing at least 300 mg rucaparib.

News Article | May 23, 2017

SAN FRANCISCO--(BUSINESS WIRE)--The Pancreatic Cancer Action Network’s San Francisco Affiliate invites everyone to join PurpleStride San Francisco on June 18, at Justin Herman Plaza. Diane Borrison, a Bay Area resident, understands the importance of PurpleStride and its impact on the pancreatic cancer community – both locally and nationally. “As an 11-year pancreatic cancer survivor, I have a responsibility to do all I can to change the course of this devastating disease,” Borrison said. “I choose to fundraise for PurpleStride because I know that the money raised will be used to advance critical pancreatic cancer research and clinical initiatives. Through fundraising, we can create a better future for all pancreatic cancer patients.” Each year, more than 80,000 people in cities across the United States Wage Hope at PurpleStride, the walk to end pancreatic cancer. Each participant walks to improve outcomes for the nation’s deadliest cancer, one that has a five-year survival of just 9 percent. Funds raised through PurpleStride allow the Pancreatic Cancer Action Network (PanCAN) to attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Since 2003, the Pancreatic Cancer Action Network has awarded 142 grants to 143 scientists at 55 institutions, totaling $35.4 million. In addition to supporting research grants, PanCAN supports key initiatives like Precision PromiseSM, Know Your Tumor® and the Patient Registry. “Our goal at the Pancreatic Cancer Action Network is to double survival by 2020 and we are committed to making that happen,” said Julie Fleshman, JD, MBA, President and CEO of the Pancreatic Cancer Action Network. “PurpleStride is allowing us to fund key initiatives that will improve patient outcomes and ultimately help us reach our 2020 goal.” PurpleStride San Francisco will be hosted by National Emmy Award winner and CBS San Francisco anchor Joe Vazquez and will include kid-friendly activities and a purple play zone. The San Francisco event is supported by national presenting sponsor Celgene; national gold sponsor AbbVie; regional gold sponsor Cancer Treatment Centers of America, gold sponsor Halozyme, gold media sponsor KPIX5/KBCW 44 Cable 12, and silver sponsor Clovis Oncology. To register, donate or learn more about PurpleStride San Francisco, please visit For more on PurpleStride and the Pancreatic Cancer Action Network, watch the PurpleStride PSA and the organization’s PSA. Follow the Pancreatic Cancer Action Network on Twitter, Instagram or on Facebook. The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world’s toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes today and to double survivor by 2020.

Loading Clovis Oncology collaborators
Loading Clovis Oncology collaborators